Role of Adiposomes in Endothelial Dysfunction

Obesity Clinical Trial

Official title:

Role of Adiposomes in Diabetes-Associated Endothelial Dysfunction and Restorative Effects of Exercise and Metabolic Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05199454
• Other study ID #: 2021-1113
• Secondary ID: 1R01HL161386-01
• Status: Recruiting
• Phase: N/A
• Start date: May 16, 2022
• Est. completion date: December 31, 2026

Study information

• Verified date: November 2023
• Source: University of Illinois at Chicago
• Contact: Abeer M Mohamed, MD, PhD
• Phone: 312-355-8099
• Email: amahmo4[@]uic.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective strategies that target these mechanisms such as physical activity and weight loss. The investigators recently discovered that human adipose tissues release extracellular vesicles (adiposomes) that are efficiently captured by endothelial cells. Adiposomes are known to carry bioactive cargos such as proteins and micro RNAs; however, their lipid content has not been studied nor has their ability to transfer their lipid cargo to endothelial cells. In the current application, the investigators propose to investigate the role of adiposomes in communicating the unhealthy milieu, mainly dysregulated lipids, to endothelial cells in OB-T2D subjects. On top of these lipid species that the investigators propose to be carried by adiposomes are glycosphingolipids (GSLs). These lipids originate from the glycosylation of ceramides, a chemical process that is upregulated in the presence of inflammation and high glucose levels. Preliminary findings showed that in endothelial cells, GSL-rich adiposomes disturb plasma membrane structure and subsequently induce endothelial dysfunction. Moreover, the investigators found that preconditioning endothelial cells with high shear stress (which is an exercise mimetic) protected endothelial cells from the detrimental effects induced by adiposomes. Therefore, the central hypothesis is that adipose tissues in OB-T2D patients release GSL-loaded adiposomes that induce vascular endothelial dysfunction. The researchers propose that exercise and weight loss interventions (bariatric surgery) will restore adipose tissue homeostasis, reduce GSL-loaded adiposomes, and subsequently alleviate vascular risk in OB-T2D patients. The investigators will test the hypotheses by pursuing the following aims: aim 1: Investigate the role of GSL-rich adiposomes in the pathogenesis of endothelial dysfunction in OB-T2D adults; aim 2: Test the effectiveness of exercise training in reducing adiposome-mediated effects on vascular function; and aim 3: Examine changes in adiposome/caveolae axis following metabolic surgery and their association with vascular function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• BMI = 35 kg/m2
• Between ages 18-50 years
• Not pregnant
• Diabetic (Current use of diabetes medication or fasting glucose =126 mg/dL)
• Medical clearance to participate in a moderate-intensity exercise program

Exclusion Criteria:

• Pregnant women
• Current smokers
• Currently abusing alcohol or drugs
• Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer
• Non-English speakers
• History of allergic reactions to lidocaine

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes
• Obesity

Intervention

Other:
• Exercise training
Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.

Locations

Country	Name	City	State
United States	University of Illinois at Chicago	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Illinois at Chicago	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brachial artery flow-mediated dilation (percent vasodilation) in 60 obese diabetic subjects	Brachial flow-mediated dilation will be measured using ultrasound Alpha 7. For recording, a linear probe will be positioned five centimeters above the left arm's antecubital fossa, and a 1-minute baseline imaging will be recorded. Then, a blood pressure cuff will be put around the right mid-forearm and inflated to 200 to 220 mmHg for 5 minutes. Following cuff deflation (reactive hyperemia), a video grabber will be used to record a 300-second video sequence at three frames per second for offline measurement. The greatest brachial artery diameter at baseline will be deducted from the largest mean values obtained following cuff deflation to determine relative flow mediated dilation	4 years
Secondary	Glycosphingolipid content (ng/ml) in adiposomes from 60 obese diabetic subjects	Adiposomes isolated from adipose tissue samples will be examined for their glycosphingolipid content using mass spectrometry and the outcome will be in nanograms per milliliter (ng/ml)	4 years